ATA100695A - Prothrombin-derivate - Google Patents

Prothrombin-derivate

Info

Publication number
ATA100695A
ATA100695A AT0100695A AT100695A ATA100695A AT A100695 A ATA100695 A AT A100695A AT 0100695 A AT0100695 A AT 0100695A AT 100695 A AT100695 A AT 100695A AT A100695 A ATA100695 A AT A100695A
Authority
AT
Austria
Prior art keywords
prothromine
derivatives
prothromine derivatives
Prior art date
Application number
AT0100695A
Other languages
English (en)
Other versions
AT404357B (de
Inventor
Bernhard Fischer
Uwe Schlokat
Artur Mitterer
Falko-Guenter Falkner
Johann Eibl
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0100695A priority Critical patent/AT404357B/de
Application filed by Immuno Ag filed Critical Immuno Ag
Priority to CA002224634A priority patent/CA2224634A1/en
Priority to EP96915903A priority patent/EP0833897A2/de
Priority to CZ974020A priority patent/CZ402097A3/cs
Priority to PCT/AT1996/000105 priority patent/WO1996041868A2/de
Priority to US08/952,967 priority patent/US6086871A/en
Priority to JP9502398A priority patent/JPH11507542A/ja
Priority to AU58871/96A priority patent/AU700631B2/en
Priority to HU9900506A priority patent/HUP9900506A3/hu
Priority to AT180596A priority patent/AT404516B/de
Publication of ATA100695A publication Critical patent/ATA100695A/de
Application granted granted Critical
Publication of AT404357B publication Critical patent/AT404357B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT0100695A 1995-06-13 1995-06-13 Prothrombin-derivate AT404357B (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AT0100695A AT404357B (de) 1995-06-13 1995-06-13 Prothrombin-derivate
EP96915903A EP0833897A2 (de) 1995-06-13 1996-06-12 Prothrombin-derivate
CZ974020A CZ402097A3 (cs) 1995-06-13 1996-06-12 Deriváty prothrombinu
PCT/AT1996/000105 WO1996041868A2 (de) 1995-06-13 1996-06-12 Prothrombin-derivate
CA002224634A CA2224634A1 (en) 1995-06-13 1996-06-12 Prothrombin derivatives
US08/952,967 US6086871A (en) 1995-06-13 1996-06-12 Prothrombin derivatives
JP9502398A JPH11507542A (ja) 1995-06-13 1996-06-12 プロトロンビン誘導体
AU58871/96A AU700631B2 (en) 1995-06-13 1996-06-12 Prothrombin derivatives
HU9900506A HUP9900506A3 (en) 1995-06-13 1996-06-12 Prothrombin derivatives
AT180596A AT404516B (de) 1995-06-13 1996-10-14 Vorrichtung zur quantifizierung von prothrombin-derivaten

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0100695A AT404357B (de) 1995-06-13 1995-06-13 Prothrombin-derivate

Publications (2)

Publication Number Publication Date
ATA100695A true ATA100695A (de) 1998-03-15
AT404357B AT404357B (de) 1998-11-25

Family

ID=3504770

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0100695A AT404357B (de) 1995-06-13 1995-06-13 Prothrombin-derivate

Country Status (9)

Country Link
US (1) US6086871A (de)
EP (1) EP0833897A2 (de)
JP (1) JPH11507542A (de)
AT (1) AT404357B (de)
AU (1) AU700631B2 (de)
CA (1) CA2224634A1 (de)
CZ (1) CZ402097A3 (de)
HU (1) HUP9900506A3 (de)
WO (1) WO1996041868A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231210D1 (de) 2001-07-06 2009-04-02 Chemo Sero Therapeut Res Inst Verfahren zur herstelllung von menschlichem thrombin mittels genmodifikationstechnik
AU2008202376B2 (en) * 2001-07-06 2011-02-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing human thrombin by gene modification technique
US20030099957A1 (en) * 2001-09-28 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
WO2006104398A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
EP2399994A1 (de) 2006-11-15 2011-12-28 Fujimori Kogyo Co., Ltd. Thrombin-Mutant
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
AU2009320153B2 (en) * 2008-10-27 2016-07-14 Trustees Of Tufts College Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds, and uses thereof
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
EP2453910B1 (de) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Einzeldosisformulierung von antidoten für faktor-xa-hemmer zur prävention von blutung
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
EP2471945A1 (de) * 2010-12-30 2012-07-04 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Bestimmung von Inhibitoren der Gerinnung
EA201301090A1 (ru) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Антидоты антикоагулянтов
EP2874646A4 (de) * 2012-04-17 2016-07-06 Univ Aarhus Sorcs1 zur verwendung bei der behandlung von adipositas und übergewicht
GB2504499A (en) * 2012-07-31 2014-02-05 Baxter Healthcare Sa Selective measurement of active human protease coagulation factors
NZ727444A (en) 2014-05-26 2021-12-24 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
CA2000887A1 (en) * 1988-11-01 1990-05-01 Cecilia S.L. Ku Thromboresistant materials and methods for making same
DE69017236T3 (de) * 1989-01-25 1999-11-25 Novartis Ag, Basel Monoklonale Antikörper, spezifisch für Hirudin.
FI923347A0 (fi) * 1990-01-26 1992-07-23 Immuno Ag Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
US6110721A (en) * 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
AT401270B (de) * 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna

Also Published As

Publication number Publication date
CA2224634A1 (en) 1996-12-27
JPH11507542A (ja) 1999-07-06
HUP9900506A3 (en) 2001-10-29
AU5887196A (en) 1997-01-09
WO1996041868A2 (de) 1996-12-27
HUP9900506A2 (hu) 1999-06-28
AT404357B (de) 1998-11-25
US6086871A (en) 2000-07-11
AU700631B2 (en) 1999-01-07
WO1996041868A3 (de) 1997-04-10
CZ402097A3 (cs) 1998-04-15
EP0833897A2 (de) 1998-04-08

Similar Documents

Publication Publication Date Title
DE69611361D1 (de) Chinazolin-derivate
DE69522717D1 (de) Chinazolinderivate
NO974103L (no) Arylsulfonylaminohydroksamsyre-derivater
DE69610698D1 (de) Chinazolin-derivate
PT833828E (pt) Derivados de rapamicina
BR9611834A (pt) Derivados de oximetóxi-3-aril-pirona
ATE199150T1 (de) Diphenylmethylenpiperidin-derivate
NO964667D0 (no) Purin-6-on-derivater
DE69601527D1 (de) Pyrrolylbenzimidazol-Derivate
PT856007E (pt) Derivados de ciclopeptidos
ATE240307T1 (de) Diarylalkenylamin-derivate
DE69627830D1 (de) Pyrazol-derivate
NO961404D0 (no) 4-indolylpiperazinyl-derivater
ATE202093T1 (de) 4-amino-benzoylguanidin-derivate
DE59610106D1 (de) Fluorbenzylether-Derivate
ATE177102T1 (de) Chromanderivate
DK0843675T3 (da) Aza-anthracyclinonderivater
BR9603508A (pt) Derivados de alquenil-benzoilguanidina
ATE202088T1 (de) 4-mercapto-benzoylguanidin-derivate
DE69620514D1 (de) 5-aminoflavon-derivate
ATE240972T1 (de) Cyclopeptolide
ATA45796A (de) Lysin-prolin-derivate
BR9603733A (pt) Derivados de cloropiridilcarbonila
DK0705833T3 (da) DC-89-derivat
FI1959U1 (fi) Vaggmede

Legal Events

Date Code Title Description
MK07 Expiry

Effective date: 20150613